Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma

International Journal of Cancer

Volumn 130, Issue 11, 2012, Pages 2591-2598

  De Brouwer, Sara ^a   Mestdagh, Pieter ^a   Lambertz, Irina ^a   Pattyn, Filip ^a   De Paepe, Anne ^a   Westermann, Frank ^b   Schroeder, Christina ^b   Schulte, Johannes H ^c   Schramm, Alexander ^c   De Preter, Katleen ^a   Vandesompele, Jo ^a   Speleman, Frank ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

dickkopf 3; miR 17 92 cluster; neuroblastoma

Indexed keywords

DICKKOPF 3 PROTEIN; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 17 92; MICRORNA 19B; MICRORNA 92A; ONCOPROTEIN; PROTEIN MYCN; RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CANCER LOCALIZATION; CANCER PROGNOSIS; CONTROLLED STUDY; DICKKOPF 3 GENE; DOWN REGULATION; ENZYME ASSAY; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; MYCN GENE; NEUROBLASTOMA; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA STABILITY; RNA TRANSLATION; UPREGULATION;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; UP-REGULATION;

EID: 83655166202     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26295     Document Type: Article

References (41)

1. Maris JM,. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-11.
2. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA,. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010; 293: 144-57.
3. Luscher B,. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001; 277: 1-14.
4. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM,. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-95.
5. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M,. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13: 803-12.
6. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 2008; 122: 699-704.
7. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N,. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006; 66: 2826-33.
8. Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Pahlman S, Guzhova I, Larsson LG,. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells. Mol Cancer Ther 2007; 6: 2634-41.
9. Nakamura M, Matsuo T, Stauffer J, Neckers L, Thiele CJ,. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ 2003; 10: 230-9.
10. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH,. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 2006; 351: 192-7.
11. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fukuzawa M,. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 2007; 30: 1189-96.
12. Woo CW, Tan F, Cassano H, Lee J, Lee KC, Thiele CJ,. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer 2008; 50: 208-12.
13. Mac SM, D'Cunha CA, Farnham PJ,. Direct recruitment of N-myc to target gene promoters. Mol Carcinog 2000; 29: 76-86.
14. Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner MK, Nuchtern JG,. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002; 62: 1123-8.
15. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM,. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005; 102: 731-6.
16. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, Konig R, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008; 9: R150.
17. Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, Herold S, Eilers M, Bernardoni R, Della Valle G, Perini G,. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res 2011; 71: 404-12.
18. Bell E, Lunec J, Tweddle DA,. Cell cycle regulation targets of MYCN identified by gene expression microarrays. Cell Cycle 2007; 6: 1249-56.
19. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C,. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998; 391: 357-62.
20. Kawano Y, Kypta R,. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116: 2627-34.
21. Mao B, Niehrs C,. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 2003; 302: 179-83.
22. Wu W, Glinka A, Delius H, Niehrs C,. Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 2000; 10: 1611-14.
23. Koppen A, Ait-Aissa R, Koster J, Ora I, Bras J, van Sluis PG, Caron H, Versteeg R, Valentijn LJ,. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN. Int J Cancer 2008; 122: 1455-64.
24. Revet I, Huizenga G, Koster J, Volckmann R, van Sluis P, Versteeg R, Geerts D,. MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. Cancer Lett 2010; 289: 195-207.
25. Kobayashi K, Ouchida M, Tsuji T, Hanafusa H, Miyazaki M, Namba M, Shimizu N, Shimizu K,. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 2002; 282: 151-8.
26. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H,. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65: 4218-27.
27. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Barrios M, Andreu EJ, Prosper F, Heiniger A, Torres A,. Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. Br J Cancer 2004; 91: 707-13.
28. Tsuji T, Nozaki I, Miyazaki M, Sakaguchi M, Pu H, Hamazaki Y, Iijima O, Namba M,. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Commun 2001; 289: 257-63.
29. Abarzua F, Sakaguchi M, Takaishi M, Nasu Y, Kurose K, Ebara S, Miyazaki M, Namba M, Kumon H, Huh NH,. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res 2005; 65: 9617-22.
30. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R,. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004; 64: 2734-9.
31. Hsieh SY, Hsieh PS, Chiu CT, Chen WY,. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004; 23: 9183-9.
32. Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM,. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 2006; 25: 6528-37.
33. Kuphal S, Lodermeyer S, Bataille F, Schuierer M, Hoang BH, Bosserhoff AK,. Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene 2006; 25: 5027-36.
34. Kurose K, Sakaguchi M, Nasu Y, Ebara S, Kaku H, Kariyama R, Arao Y, Miyazaki M, Tsushima T, Namba M, Kumon H, Huh NH,. Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol 2004; 171: 1314-8.
35. Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J, Chae M, Zhang W, Lee JH,. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer 2009; 124: 287-97.
36. Tsuji T, Miyazaki M, Sakaguchi M, Inoue Y, Namba M,. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 2000; 268: 20-4.
37. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, Kumps C, Schlierf S, De Preter K, Van Roy N, Noguera R, Laureys G, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010; 29: 1394-404.
38. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquiere B, Schulte S, Dews M, Thomas-Tikhonenko A, Schulte JH, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010; 40: 762-73.
39. Lefever S, Vandesompele J, Speleman F, Pattyn F,. RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res 2009; 37: D942-5.
40. Clevers H,. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
41. Tudzarova S, Trotter MW, Wollenschlaeger A, Mulvey C, Godovac-Zimmermann J, Williams GH, Stoeber K,. Molecular architecture of the DNA replication origin activation checkpoint. EMBO J 2010; 29: 3381-94.